Evidence map›Paper›PMID 42789583›Full record

ArticlePloS one2026

Integrative computational analysis of public fecal lipidomics and transcriptomics datasets suggests a candidate association between the COX-2 pathway and CE(20:4) in colorectal adenoma-carcinoma progression.

Bing Tang, Yanru Chen, Xia Yang, Hanlin Gong

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bing TangDivision of Surgery, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
Yanru ChenDepartment of Rehabilitation, The People's Hospital of Jianyang City, Jianyang, China.
Xia YangDivision of Surgery, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
Hanlin GongDivision of Surgery, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-5658-9841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe fecal lipidomic changes underlying the colorectal adenoma-carcinoma sequence remain incompletely characterized, particularly regarding the continuous metabolic trajectory and heterogeneity of precancerous adenomas. We aimed to use publicly available multi-omics data and an integrative computational framework to identify candidate lipidomic features associated with a CRC-like metabolic state in adenomas.

methodsWe developed an extreme-phenotype machine learning strategy using fecal lipidomics from healthy controls and colorectal cancer (CRC) patients (Study ID: ST003798) to build a diagnostic model, which was then blindly applied to adenoma patients to compute a Fecal Lipidomic Malignancy Risk Score (FL-MRS), interpreted here as a CRC-like lipidomic similarity score. SHAP analysis prioritized influential lipid features, and cross-sectional pseudotime trajectory inference reconstructed the metabolic continuum. Transcriptomic data from TCGA-COAD and single-cell RNA-seq (Broad Institute) were integrated to explore potential tissue-level correlates. Targeted single-molecule trend verification of the top lipid candidate was performed in an independent cohort (ST002787), as full model replication was not feasible due to limited inter-cohort feature overlap. Multiple sensitivity analyses were conducted to assess the robustness of the computational pipeline.

resultsThe Random Forest model showed robust performance on the independent test set (AUC = 0.864). When applied to adenomas, 51.7% of patients exceeded the FL-MRS threshold derived from extreme phenotypes; however, this proportion far exceeds the known clinical adenoma-carcinoma progression rate (approximately 5-10%), indicating that FL-MRS should be interpreted as a metabolic similarity metric rather than a direct cancer risk probability. SHAP analysis prioritized arachidonic acid-derived cholesterol ester CE(20:4) as the top predictive feature, with 100% bootstrap selection frequency. Integrative analysis of independent transcriptomic datasets identified upregulation of PTGS2 (COX-2) in tumor tissue and its predominant expression in stromal cells. External single-molecule targeted verification confirmed an accumulation trend of CE(20:4) and an early adenoma-phase peak of eicosanoid mediators (including oxidative stress and LOX-pathway metabolites). Notably, CE(20:4) levels did not differ significantly between adenoma and CRC (P = 0.055), consistent with its proposed role as an early event marker. Pseudotime trajectory inference was insensitive to root node assignment.

conclusionsThis computational study suggests that fecal CE(20:4) and the associated COX-2 pathway may represent candidate features of a CRC-like metabolic state in colorectal adenomas. FL-MRS is not proposed as a clinical diagnostic or risk-prediction tool; rather, it serves as a research instrument for quantifying CRC-like metabolic similarity and guiding future validation studies. All findings are derived from publicly available retrospective data without independent experimental validation and should be regarded as hypothesis-generating. The complete analysis code is publicly archived to ensure reproducibility and facilitate future validation.

Indexed as

AdenomaColorectal NeoplasmsCyclooxygenase 2FecesLipidomicsTranscriptomeComputational BiologyDisease ProgressionGene Expression ProfilingHumansMultiomicsCyclooxygenase 2

Identifiers

PMID42789583
PMCPMC13614635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.